Sotabase

Career

· TA Of CS176, CS251, CS253, Purdue University2023–
· Summer Internship, Purdue University2022–2022
· Algorithm Engineer, Zhongke Wenge Science and Technology Co., Ltd2022–2022
· Online course completion, Computer Science, 85/100, Massachusetts Institute of Technology2021–2021
· Bachelor of Science - BS, Computer Science, 3.78/4.0, Tianjin University2019–2023

Publications (33)

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology · 2014
418
cited
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Journal of the American Medical Association (JAMA) · 2015
390
cited
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Hepatology · 2018
198
cited
MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection
2017
62
cited
IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study
Clinical Hepatology · 2019
58
cited
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
Journal of Infection · 2015
44
cited
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Drug and Alcohol Dependence · 2019
35
cited
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir
Journal of Infectious Diseases · 2017
23
cited
Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
Journal of the International AIDS Society · 2014
21
cited
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
Open Forum Infectious Diseases · 2017
16
cited
Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials
Journal of Viral Hepatitis · 2020
13
cited
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
American Journal of Gastroenterology · 2021
12
cited
Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis
2017
12
cited
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
Open Forum Infectious Diseases · 2022
8
cited
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada
Journal of the International AIDS Society · 2015
5
cited
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19
Pharmacology Research & Perspectives · 2022
4
cited
1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks
Open Forum Infectious Diseases · 2018
3
cited
A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
2018
3
cited
P1331 : Phase 3B studies to assess long-term clinical outcomes in HCV GT1-infected patients treated with ombitasvir/ paritaprevir/ritonavir and dasabuvir with or without ribavirin
2015
3
cited
Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection Genotype 1 and 6 and Chronic Kidney Disease: An Integrated Analysis
2017
3
cited
Sotabase
Yiran Hu | Researcher Profile | Sotabase | Sotabase